Position statement on the use of biosimilars in inflammatory bowel disease.

Burri, Emanuel; Juillerat, Pascal; Maillard, Michel H; Manz, Michael; Michetti, Pierre; Mottet, Christian; Rogler, Gerhard; Zahnd, Nadine; Vavricka, Stephan (2019). Position statement on the use of biosimilars in inflammatory bowel disease. Swiss medical weekly, 149, w20148. EMH Media 10.4414/smw.2019.20148

Preview

Text smw_2019_20148.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (602kB) | Preview

Biologics are effective and have a good safety profile in the treatment of inflammatory bowel disease. Biosimilars have recently become available as treatment option. They are biological agents that are highly similar to the original biologic compound in their structure, biological activity, efficacy and safety. This position paper summarises current knowledge on biosimilars and presents its statements on regulatory issues and clinical situation in order to provide clinicians adequate information for them to reach informed and appropriate shared decision-making with their patients.

Interest & Impact

Downloads

117 since deposited on 23 Jan 2020
22 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item